These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2163227)

  • 21. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
    Andrassy K
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S39-43. PubMed ID: 8180328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Past, present and future considerations on low molecular weight heparin differentiation: an epilogue.
    Fareed J; Haas S; Sasahar A
    Semin Thromb Hemost; 1999; 25 Suppl 3():145-7. PubMed ID: 10549730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability.
    Kitchen S; Iampietro R; Woolley AM; Preston FE
    Thromb Haemost; 1999 Oct; 82(4):1289-93. PubMed ID: 10544915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
    Clark NP
    Thromb Res; 2008; 123 Suppl 1():S58-61. PubMed ID: 18809206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hemorrhages among patients treated with low-molecular-weight heparins].
    Vallano Ferraz A; Pedrós Cholvi C; Montané Esteva E; Bejarano Romero F; López Andrés A; Cereza García G; Arnau de Bolós JM
    Rev Clin Esp; 2002 Nov; 202(11):583-7. PubMed ID: 12392644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of standard unfractionated and low-molecular-weight heparins on platelets of patients undergoing total hip replacement surgery.
    Aulmann M; Kwasniki S; Böttiger BW; Meeder PJ
    Beitr Infusionsther Transfusionsmed; 1997; 34():242-7. PubMed ID: 9356680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Biological monitoring of treatment with low molecular weight heparin].
    Aiach M; Sié P
    Ann Biol Clin (Paris); 1988; 46(9):715-8. PubMed ID: 2851948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low molecular weight heparins: are they different?
    Fareed J; Hoppensteadt D; Jeske W; Clarizio R; Walenga JM
    Can J Cardiol; 1998 Aug; 14 Suppl E():28E-34E. PubMed ID: 9779031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery.
    Douketis JD; Kinnon K; Crowther MA
    Thromb Haemost; 2002 Jul; 88(1):37-40. PubMed ID: 12152674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin.
    Tapson VF; Hull RD
    Clin Chest Med; 1995 Jun; 16(2):281-94. PubMed ID: 7656540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A collaborative study of proposed European Pharmacopoeia reference preparations of low molecular mass heparin.
    Gray E; Heath AB; Mulloy B; Spieser JM; Barrowcliffe TW
    Thromb Haemost; 1995 Sep; 74(3):893-9. PubMed ID: 8571317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Low molecular weight heparin (CY 222) levels during hemodialysis sessions. Comparison of various chromogenic and chronometric methods. Problem of standardization].
    Roussel B; Dieval J; Bayrou B; Delobel J
    J Mal Vasc; 1987; 12 Suppl B():85-9. PubMed ID: 2834499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Low molecular weight heparins].
    Kher A; Bara L; Samama M
    Pathol Biol (Paris); 1986 Jan; 34(1):61-9. PubMed ID: 3517772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-molecular-weight heparin: an antithrombotic agent whose time has come.
    Futterman LG; Lemberg L
    Am J Crit Care; 1999 Jan; 8(1):520-3. PubMed ID: 9987551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low molecular weight heparin and pregnancy.
    Prescrire Int; 2001 Oct; 10(55):147-9. PubMed ID: 11824430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.